The addition of an insulin/IGF-targeting agent to androgen deprivation therapy for prostate cancer is also supported by pre-clinical evidence, as insulin has been shown to promote androgen production by prostate cancer cells, possibly hastening the development of castration-resistant prostate cancer (151). The gene discussed is INS; the disease is prostate cancer.